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ABSTRACT 
The HLA-DRB1 alleles encoding an amino acid sequence (QKRAA/QRRAA/RRRAA) at position 70 74 of the third 
hypervariable region of the β1 chain of the HLA-DRB1 gene, called shared epitope (SE), are associated with increased 
susceptibility to and severity of rheumatoid arthritis (RA) in different populations. Objective: To determine the frequency 
of HLA-DRB1 alleles in Brazilian patients with RA and their association with rheumatoid factor (RF) and anti-citrullinated 
peptide antibodies (ACPA). Methods: Four hundred and twelve patients with RA (ACR 1987) and 215 controls were 
included. HLA-DRB1 typing was performed by use of polymerase chain reaction (PCR) with speciﬁ c primers and hy-
bridization with sequence-speciﬁ c oligonucleotide probe (SSOP). ACPA was measured by use of the ELISA technique 
and RF by nephelometry. The statistical analysis comprised the chi-square and Student t tests and logistic regression. 
Results: HLA-DRB1*04:01, *04:04, *04:05 alleles were associated with RA (P < 0.05); despite the wide conﬁ dence 
interval, it is worth noting the association between the DRB1*09:01 allele and RA (P < 0.05). HLA-DRB1 SE+ alleles 
were observed in 62.8% of the patients and in 31.1% of controls (OR 3.62; P < 0.001) and were associated with ACPA 
(OR 2.03; P < 0.001). DRB1-DERAA alleles showed a protective effect against RA (OR 0.42; P < 0.001). Conclusion: 
In a sample of Brazilian patients with RA, most of whom of mixed heritage, HLA-DRB1 SE+ alleles were associated 
with susceptibility to disease and presence of ACPA.  
Keywords: HLA-DRB1, shared epitope, rheumatoid arthritis, genetic polymorphism, immunogenetics.
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INTRODUCTION 
Rheumatoid arthritis (RA) is a chronic systemic disease char-
acterized by the inﬂ ammatory involvement of the synovial 
membrane of joints, leading to bone and cartilage destruction. 
Its prevalence in the adult population worldwide ranges from 
0.5% to 1%, being 0.46% in Brazil.1 Its peak incidence is 
between the fourth and sixth decades, and RA is three times 
more frequent in women than in men.2 
Although the etiology of RA remains unknown,3 several 
studies have suggested that a combination of genetic and 
environmental factors is involved. The genetic factor ac-
counts for  approximately 60% of the susceptibility to RA.4 
Although the role played by heredity has not been completely 
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understood, the major risk factor, responsible for 30% to 50% 
of the genetic component, seems to be related to human 
leukocyte antigens (HLA). The HLA is located in the ma-
jor histocompatibility complex (MHC) present in the short 
arm of chromosome 6 (6p21.3).5 A group of alleles in the 
HLA-DRB1 locus (DRB1*01:01, DRB1*01:02, DRB1*04:01, 
DRB1*04:04, DRB1*04:05, DRB1*04:08, DRB1*04:10, 
DRB1*10:01, DRB1*14:02) encodes a shared amino acid 
sequence (QKRAA/QRRAA/RRRAA, where Q = glutamine; 
K = lysine; R = arginine; and A = alanine), located in the 
peptide binding site, at position 70-74 of the third hyper-
variable region of the HLA-DR molecule, a sequence called 
shared epitope (SE).6 
The SE is believed to be involved in the pathogenesis of 
RA, because it serves as a binding site in the process of arth-
ritogenic peptide presentation to CD4+ T cells involved in the 
immune inﬂ ammatory response of this disease. Moreover, the 
SE can be involved in the process of inducing some B cells 
to differentiate into plasma cells, leading to the formation of 
anti-citrullinated peptide antibodies (ACPA).7 In addition to its 
role in susceptibility to RA, alleles containing the SE sequences 
(mainly homozygous) are associated with more severe forms 
of disease and extra-articular manifestations,8 and also with 
the presence of erosive disease.9,10 
Studies conducted in several ethnic groups have shown the 
existence of  considerable variations regarding the association of 
HLA-DRB1 alleles with susceptibility to RA.11 The following 
associations of the HLA-DRB1 alleles, susceptibility to RA and 
ethnic groups have been reported: HLA-DRB1*04:01 and *04:04 
alleles in Caucasians of Northern Europe and the United States;12 
DRB1*04:05 alleles in Koreans, Japanese, and Chinese;13,14 
DRB1*01:01 and *10:01 alleles in Greeks, Spaniards, and Israeli 
Jews;15,16 DRB1*14:02 alleles in Native American, Peruvian17,18 
and Ecuadorean19 Indians; and DRB1*04:04 alleles in Colombians 
and Argentians.20,21 In Brazil, Bertolo et al.22 have reported an as-
sociation of RA with DRB1*01:01 and *01:02 in 65 Caucasians 
patients. More recently, Louzada-Junior et al.23 have reported an 
association of the disease with the DRB1*04:01, *04:04, *04:05, 
*01:01, and *10:01 alleles in 140 patients, most of whom of 
Caucasian ethnicity. 
However, the HLA-DRB1 alleles, with a common amino 
acid sequence, DERAA (D = aspartic acid, E = glutamic acid, 
R = arginine, A = alanine), expressed in the DRB1*01:03, 
*04:02, *11:02, *11:03, *13:01, 13:02 and *13:04 alleles, 
seem to be associated with a lower risk for developing RA, 
despite the presence of SE. The presence of these alleles also 
seems to protect against severe erosive disease, even in patients 
with ACPA.24,25 
The main immunological markers of RA, rheumatoid factor 
(RF) and ACPA, also seem to be involved in the pathogenesis 
of rheumatoid synovitis. High titers of both markers have 
been associated with more aggressive and erosive disease.26,27 
Some studies in patients with RA have shown controversial 
results regarding the association with SE and positivity for 
RF.28,29 At the same time, there seems to be an association 
of SE+ alleles only in patients with RA who are positive for 
ACPA,30 and this association would be more intense with ACPA 
than with RA itself.31 This association suggests that the SE alleles 
could inﬂ uence the antigen presentation, leading to the produc-
tion of ACPA. More recently, the risk carried by smoking, the 
main environmental factor, was observed to be particularly high 
in individuals with HLA-DR SE+ alleles and ACPA.32 
Considering the diversity of the results in literature regard-
ing the association of HLA-DRB1 alleles with RA in different 
ethnicities, this study aimed at determining the association 
between these alleles and RA, including the presence of RF 
and/or ACPA, in Brazilian patients of highly mixed heritage. 
MATERIAL AND METHODS 
Patients and control
This was a case-control study with RA patients, all of whom 
met at least four of the seven criteria for the diagnostic clas-
siﬁ cation of RA established by the American College of 
Rheumatology (ACR).33 The patients selected had no other 
autoimmune diseases and were regularly followed-up at the 
outpatient clinics of RA of the discipline of Rheumatology of 
the Hospital Universitário Pedro Ernesto of the Universidade 
Estadual do Rio de Janeiro (UERJ) and the Hospital São Paulo 
of the Universidade Federal de São Paulo (UNIFESP), from 
October 2007 to August 2009. The control group comprised 
volunteer bone marrow donors from donation campaigns car-
ried out in different neighborhoods of the city of Rio de Janeiro 
from May 2008 to November 2009. The donors were of both 
genders, had neither current nor past complaint of arthritis, and 
their ages ranged from 18 to 55 years. Individuals with a fam-
ily history of RA or other autoimmune diseases in ﬁ rst-degree 
relatives were excluded from the study. Individuals older than 
30 years were selected to minimize the analysis bias regarding 
a possible future diagnosis of this disease in the group. 
After being informed about the nature of the study and 
having provided written informed consent, the participants 
underwent a clinical interview with a standardized form 
for both groups. Demographic data were collected for both 
groups, and clinical characteristics for the group of patients. 
Both groups underwent blood collection for HLA typing. The 
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group of patients also underwent autoantibody detection (RF 
and ACPA).
The groups were paired for sex and ethnicity. The ethnic 
origin was attributed by the same investigator, after asking 
the patients and volunteer donors about their ancestors. Black 
or Caucasian ethnicity was attributed to an individual whose 
all four grandparents were of Black or Caucasian ethnicity, 
respectively; the mixed ethnicity was attributed to an indi-
vidual when at least one of his/her grandparents had a different 
ethnicity. No Asian descendant was included in the study to 
avoid a selection bias. 
Individuals who did not have sufﬁ cient DNA or serum 
amount for an adequate analysis of HLA typing or autoantibody 
measurement in the two groups were excluded. Individuals 
whose HLA typing was ambiguous were not included. 
HLA-DRB1 typing
The HLA-DRB1 alleles were determined for all RA patients 
and controls. The HLA typing was performed with the poly-
merase chain reaction (PCR) using speciﬁ c primers and hy-
bridization with the speciﬁ c sequence oligonucleotide probe 
(SSOP) (One Lambda Inc., Canoga Park, CA, USA). 
Deﬁ nition of HLA-DRB1 alleles posing risk for RA
All individuals typed for the HLA-DRB1*01:01, *01:02, 
*04:01, *04:04, *04:05, *04:08, *04:10, *10:01 and *14:02 
alleles were considered as having the SE (SE+), which could 
be present in a single (SE+/-) or double dose (SE+/+). Risk 
associations for RA between HLA-DRB1 alleles were per-
formed based on genotypic combinations established in the 
absence of the SE (-/-), and in the presence of a single (SE+/-) 
or double dose of the SE (SE+/+). The HLA-DRB1 alleles 
were also associated with the serological characteristics of 
RA patients. 
Deﬁ nition of the protective HLA-DRB1 alleles against RA
All individuals typed for the HLA-DRB1*01:03, *04:02, 
*11:02, *11:03, *13:01, *13:02 and *13:04 alleles were con-
sidered as having the DERAA sequence (protective), which 
could be present in a single or double dose.
Individuals with typing comprising alleles that did no 
belong to the sequence of SE or DERAA were deﬁ ned as X, 
which could be present in a single or double dose. 
Thus, the following six groups of individuals, according 
to the presence of DRB1 alleles, were analyzed:
Group A: double dose (homozygous) of SE allele (SE/SE);
Group B: single dose (heterozygous) of SE allele (SE/X); 
Group C: single dose of SE and DERAA alleles (SE/DERAA); 
Group D: lack of SE and DERAA alleles (X/X); 
Group E: single dose of DERAA allele (DERAA/X);
Group F: double dose of DERAA allele (DERAA/DERAA).
Measuring RF and ACPA
The ACPA was measured using the second generation 
QUANTA LiteTM CCP IgG ELISA (INOVA Diagnostics, Inc., 
San Diego, USA) according to the instructions of the manufac-
turer. The IgM RF was quantiﬁ ed using the nephelometry tech-
nique (Dade Behring Marburg GmbH – Germany). Regarding 
IgM RF, values > 20 UI/mL were considered positive, while 
values > 100 UI/mL were considered high titers. Regarding 
ACPA, titers > 20 U/mL were considered positive, while those 
> 60 U/mL were considered high.
Statistical analysis
Data were assessed using the Epi Info 6 program. The as-
sociation analysis between the categorical variables was 
performed by chi-square test (Yates correction) or Fisher 
exact test. Quantitative variables with normal distribution 
was assessed by Student t test for independent samples or 
Mann-Whitney test, and of analysis of variance. P < 0.05 
was considered statistically signiﬁ cant. Logistic regres-
sion was used to categorize the risk of the association with 
HLA-DRB1 alleles.
RESULTS
This study included 412 (95%) of 430 patients with RA and 
215 (74%) controls of 290 volunteer bone marrow donors 
interviewed. Gender and ethnicity were similar in both groups 
(P = 0.722 and P = 0.552). The other demographic, clinical, 
and laboratory data of RA patients and controls are shown in 
Table 1.
Association of HLA-DRB1 allele groups with RA
Table 2 shows the distribution of the frequencies of HLA-DRB1 
allele groups and their association with susceptibility to and 
protection against RA in 412 patients with RA and 215 volun-
teers in the control group. The HLA-DRB1*04 (OR = 2.69), 
*09 (OR = 5.19) and *14 (OR = 2.26) alleles were associated 
with susceptibility to RA (P < 0.05), while the DRB1*11 
(OR = 0.45) and *13 (OR = 0.53) alleles were associated with 
protection against the development of RA (P < 0.05). Similarly, 
when using high resolution HLA-DRB1 allele typing (Table 3), 
the analysis of allele frequencies showed that the DRB1*04:01 
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Table 1 
Demographic, clinical, and laboratory characteristics of RA patients and controls 
Variable RA (n = 412) Controls (n = 215) P
Age (mean ± SD, years) 51.8 ± 11.5/52.5 42.6 ± 5.4 < 0.001
Female gender (%) 376 (90.8) 198 (92.1) 0.722
Ethnicity 0.552
Mixed (%) 272 (66) 147 (68.4)
White (%) 111 (27) 58 (27)
Black (%) 29 (7) 10 (4.7)
Duration of disease (mean ± SD, years) 9.2 ± 7.5 —
RF+ (%) 257 (62.5) —
RF titers (mean ± SD, UI/mL) 288 ± 668 —
ACPA+ (%) 294 (71.3) —
ACPA titers (mean ± SD, U/mL) 135 ± 51.5 —
RA: rheumatoid arthritis; ACPA: anti-citrullinated peptide antibodies; RF: rheumatoid factor; SD: standard deﬁ nition.
Table 2 
Frequencies of HLA-DRB1 allele groups (low resolution) in RA patients and controls
Allele groups RA = 412, n(%) Controls = 215, n(%) OR 95% CI P
*01 113 (14) 45 (10.5) 1.36 0.93-2.00 NS
*03 73 (9) 54 (12.5) 0.68 0.46-1.00 NS
*04 186 (22.5) 42 (10) 2.69 1.86-3.92 0.001
*07 79 (9.5) 52 (12) 0.77 0.52-1.14 NS
*08 38 (5) 20 (5) 0.99 0.55-1.79 NS
*09 29 (3.5) 3 (1) 5.19 1.50-21.49 0.004
*10 27 (3) 14 (3) 1.01 0.50-2.04 NS
*11 53 (6) 57 (13) 0.45 0.30-0.68 0.001
*12 12 (1.5) 9 (2) 0.69 0.27-1.79 NS
*13 85 (10) 77 (18) 0.53 0.37-0.75 0.001
*14 38 (5) 9 (1) 2.26 1.04-5.09 0.038
*15 64 (8) 43 (10) 0.76 0.50-1.16 NS
*16 27 (3) 11 (2.5) 1.29 0.61-2.80 NS
TOTAL 824 430
RA: rheumatoid arthritis; OR: odds ratio; NS: non-signiﬁ cant.
(OR = 2.76), *04:04 (OR = 3.80), *04:05 (OR = 2.60) and 
*09:01 (OR = 5.19) alleles were associated with susceptibility 
to RA (P < 0.05).
Association of the HLA-DRB1 alleles of 
the SE with susceptibility to RA 
Table 4 shows the distribution of RA patients and controls ac-
cording to the presence of HLA-DRB1 SE+ alleles. A higher 
frequency of heterozygous (51%) than homozygous (11%) 
genotypes was observed in the group of patients, being both 
associated with susceptibility to RA (OR = 2.90, P < 0.001; and 
OR = 2.27, P < 0.001, respectively). In addition, an increased 
frequency of SE was observed in patients with RA (62.8%) 
as compared with controls (31.1%), resulting in OR = 3.59 
(P = 0.05).
The logistic regression analysis of data from RA patients 
and controls with homozygous and heterozygous genotypes 
HLA-DRB1 SE+ and SE- showed a 3.86-time increased risk 
Study of the frequency of HLA-DRB1 alleles in Brazilian patients with rheumatoid arthritis
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for the disease among patients with homozygous genotypes 
(95% CI 1.84-8.24; P < 0.001), and a 3.54-time greater risk 
among those with heterozygous genotypes (95% CI 2.40-5.21; 
P < 0.001).
Association of the HLA-DRB1-DERAA alleles 
with protection against the development of RA
Assessing the influence of the presence of DERAA al-
leles, 79 (19%) patients with RA and 78 (36%) controls 
had HLA-DRB1 alleles encoding DERAA, indicating that their 
presence protects against RA (OR = 0.42; 95% CI 0.28-0.61; 
P < 0.001). 
The effect of DERAA alleles in the absence of SE alleles 
was assessed by comparing the D (X/X) group with the 
E (X/DERAA) and F (DERAA/DERAA) groups. DERAA-
positive individuals had a lower risk for RA (OR = 0.56; 95% 
CI 0.34-0.92; P = 0.021). 
The comparison of the B (SE/X) group with the C (SE/DERAA) 
group revealed that, in the presence of a SE allele, the DERAA 
allele reduced the susceptibility to RA, although with no sta-
tistical signiﬁ cance (OR = 0.60, 95% CI 0.28-1.29; P = 0.216) 
(Table 5).
Table 3 
Allele frequency of HLA-DRB1 in RA patients and controls 
HLA-DRB1 alleles RA = 824, n(%) Controls = 430, n(%) OR 95% CI P
*01:01 68 (8.3) 26 (6) 1.40 0.86-2.29 NS
*01:02 41 (5 ) 17 (4) 1.27 0.69-2.36 NS
*01:03 4 (0.5) 2 (0.5) 1.04 0.16-8.22 NS
*03 73 (8.8) 54 (12.5) 0.68 0.46-1.00 NS
*04:01 41 (5) 8 (1.9) 2.76 1.23-6.44 0.010
*04:02 14 (1.7) 5 (1.2) 1.47 0.49-4.70 NS
*04:03 9 (1.1) 5 (1.2) 0.94 0.29-3.23 NS
*04:04 42 (5) 6 (1.4) 3.80 1.53-10.0 0.002 
*04:05 48 (5.8) 10 (2.3) 2.60 1.25-5.53 0.007
*04:06 3 (0.4) 1 (0.2) 1.57 0.15-39.2 NS
*04:07 7 (0.8) 3 (0.7) 1.22 0.28-5.97 NS
*04:08 12 (1.5) 0 (0.0) ND ND NS
*04:10 3 (0.4) 0 (0.0) ND ND NS
*04:11 7 (0.8) 4 (0.9) 0.91 0.24-3.72 NS
*07 79 (9.6) 52 (12.1) 0.77 0.52-1.14 NS
*08 38 (4.6) 20 (4.7) 0.99 0.55-1.79 NS
*09:01 29 (3.5) 3 (0.7) 5.19 1.50-21.49 0.004
*10:01 27 (3.3) 8 (1.9) 1.79 0.77-4.31 NS
*11 53 (6.4) 57 (13.2) 0.45 0.30-0.68 0.001
*12 12 (1.4) 9 (2.1) 0.69 0.27-1.79 NS
*13 85 (10.3) 77 (17.9) 0.53 0.37-0.75 0.001
*14:01 20 (2.4) 6 (1.4) 1.76 0.66-4.92 NS
*14:02 18 (2.2) 3 (0.7) 3.18 0.88-13.63 NS
*15 64 (7.8) 43 (10) 0.76 0.50-1.16 NS
*16 27 (3.3) 11 (2.6) 1.29 0.61-2.80 NS
RA: rheumatoid arthritis; OR: odds ratio; NS: non-signiﬁ cant.
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Association between susceptibility HLA-DRB1 
alleles (SE) and the presence of autoantibodies
Regarding the patients with RA, 257 (62.3%) were RF 
positive, 294 (71.3%) were ACPA positive, of whom 237 
(57.5%) were positive for both autoantibodies, and only 57 
(13.8%) were positive only for ACPA. A signiﬁ cant associa-
tion was also observed between RF and ACPA (OR = 20.79; 
95% CI 11.49-37.97; P < 0.001).
One hundred and sixty-ﬁ ve (40.04%) patients expressed 
FR+ and HLA-DRB1 SE+ alleles, and 197 (47.81%) expressed 
ACPA+ and HLA-DRB1 SE+ alleles. A signiﬁ cant association 
was observed only between SE alleles and ACPA (Table 6). 
The serum levels of RF in patients with SE homozygous 
genotypes, SE heterozygous genotypes, and genotypes with-
out SE were 177.7 ± 286 IU/mL, 205.3 ± 695 IU/mL, and 
157.1 ± 328 IU/mL, respectively. The mean ACPA serum 
levels, following the same order, were 131.3 ± 66 U/mL, 
102.8 ± 71 U/mL, and 83.3 ± 73U/mL, respectively.
Table 4
Individual speciﬁ cities of HLA-DRB1 associated with RA in Brazilians according to the presence of SE in genotypes 
SE and genotype RA = 412, n(%) Controls = 215, n(%) OR 95% IC P
SE+/SE- alleles 210 (51) 56 (26) 2.90 1.99-4.23 < 0.001
*01:01 48 (11.6) 18 (8.3) 1.44 0.79-2.65 0.257
*01:02 32 (7.7) 11 (5.1) 1.56 0.74-3.37 0.280
*04:01 23 (5.5) 6 (2.7) 2.06 0.78-5.74 0.167
*04:04 27 (6.5) 4 (1.8) 3.70 1.21-12.54 0.017
*04:05 35 (8.4) 7 (3.2) 2.76 1.15-6.94 0.020
*04:08 8 (1.9) — NS — 0.092
*04:10 3 (0.7) — NS — 0.519
*10:01 21 (5) 7 (3.2) 1.60 0.63-4.20 0.392
*14:02 13 (3.1) 3 (1.3) 2.30 0.61-10.28 0.289
SE+/SE+ alleles 45 (11) 11 (5) 2.27 1.11-4.77 0.023
*01:01/*01:01 1 (0.2) 1 (0.4) NS NS NS
*01:02/*01:02 1 (0.2) 1 (0.4) NS NS NS
*04:01/*04:01 1 (0.2) — NS NS NS
*04:04/*04:04 3 (0.7) — NS NS NS
*04:05/*04:05 1 (0.2) — NS NS NS
*14:02/*14:02 1 (0.2) — NS NS NS
*01:01/*04:01 8 (1.9) 2 (0.9) 2.11 0.41-14.50 0.532
*01:01/*04:04 3 (0.7) — NS NS NS
*01:01/*04:05 3 (0.7) 2 (0.9) NS NS NS
*01:01/*10:01 2 (0.5) — NS NS NS
*01:02/*04:01 2 (0.5) — NS NS NS
*01:02/*04:04 3 (0.7) 1 (0.9) NS NS NS
*04:01/*04:05 3 (0.7) 1 (0.9) NS NS NS
*04:01/*10:01 2 (0.5) — NS NS NS
*04:05/*10:01 2 (0.5) — NS NS NS
Outros 9 (2.2) 3 (1.3) 1.58 0.39-7.43 0.705
Total EC+ 255 (62.8) 67 (31.1) 3.59 2.49-5.17 < 0.001
RA: rheumatoid arthritis; SE+: positive shared epitope; SE-: negative shared epitope; OR: odds ratio; NS: non-signiﬁ cant.
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DISCUSSION
Genetic studies initially conducted in twins and later in their 
relatives have shown a familial predisposition to RA, repre-
senting 60% of the total risk for development of disease in 
the population.4 Several studies have shown that the most 
important genetic factor associated with susceptibility to RA 
is the presence of the HLA-DRB1 allele of MHC, discovered 
by Stastny et al.34, and later approached as the SE hypothesis 
by Gregersen et al.6
Modern techniques, such as those used in genome-wide 
association studies (GWAS) and genetic markers of single 
nucleotide polymorphism (SNP), have conﬁ rmed the sig-
niﬁ cant and preponderant association of these alleles with 
RA. However, it is worth emphasizing that the association 
between RA and HLA-DRB1 allele and the SE hypothesis 
do not explain all the genetic susceptibility resulting from 
the HLA. Other genes of the HLA, without SE, such as the 
HLA-DRB1*03:01, DRB1*07:01 and DRB1*09:01 alleles, 
although less often, have also been associated with higher 
susceptibility to RA.35,36
A second gene associated with the disease is the protein 
tyrosine phosphatase N22 (PTPN22) gene, present in 8% of RA 
patients.32 To a lesser extent, associations with the following 
alleles have been reported: the signal transducer and activator 
of transcription 4 (STAT4), cytotoxic T-lymphocyte antigen 4 
(CTLA4), macrophage migration inhibitory factor (MIF), and 
peptidylarginine deiminase type IV (PADI4).37
In the present study, 90.8% of the patients were females, 
similarly to the proportion reported by Bertolo et al.22 in 2001 
(84.6%) and by Louzada-Junior et al.23 in 2008 (77.8%).
The inﬂ uence of ethnicity is a fundamental issue when as-
sessing the association of HLA genes with diseases, especially 
with RA. In addition to being a highly polymorphic system, 
distinct alleles are associated with RA in different populations. 
Thus, when studying a population of highly mixed heritage, 
such as the Brazilian one, the traditional associations of cer-
tain ethnicities might not be observed. Aiming at controlling 
Table 5 
Frequencies of the susceptibility HLA-DRB1 genotypes for RA (SE) and 
protection against RA (DERAA) in RA patients and controls
Group HLA-DRB1 genotype RA = 412, n(%) Controls = 215, n(%)
A SE/SE 45 (10.9) 11 (5.1)
B SE/X 175 (43.2) 42 (19.5)
C SE/DERAA 35 (7.7) 14 (6.5)
D X/X 110 (26.6) 84 (39.1)
E X/DERAA 43 (10.4) 57 (26.5)
F DERAA/DERAA 4 (0.9) 7 (3.3)
SE alleles are HLA-DRB1 *01:01, *01:02, *04:01, *04:04, *04:05, *04:08, *10:01, and *14:02. DERAA alleles are HLA-DRB1 *01:03, *04:02, *11:02, *11:03, *13:01, *13:02, and *13:04. X alleles are all 
other HLA-DRB1 alleles.
OR, 95% CI and P values of the following data: Group B compared with group C: OR 0.60; 95% CI 0.28-1.29; P = 0.216. Group D compared with groups E and F: OR 0.56; 95% CI 0.34-0.92; P = 0.021. 
Group A plus group B compared with group D: OR 3.17; 95% CI 2.05-4.90; P = 0.00. 
Table 6 
Frequency of the HLA-DRB1 SE allele and autoantibodies in 412 RA patients  
Autoantibodies SE+, n(%) SE-, n(%) OR 95% IC P
Rheumatoid factor 1.26 0.82-1.94 0.313
Positive  165 (40.04) 92 (22.33)
Negative 91 (22.08) 64 (15.53)
ACPA 2.03 1.28-3.31 0.001
Positive 197 (47.81) 97 (23.54)
Negative 59 (14.32) 59 (14.32)
SE+: positive shared epitope; SE-: negative shared epitope; ACPA: anti-citrullinated peptide antibodies; OR: odds ratio.
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this variable, every study on the association between HLA 
and disease requires controls from the same sociogeographic 
stratus of  patients studied to preserve the social and demo-
graphic inﬂ uences in both groups. In addition to assessing a 
signiﬁ cant sample of RA patients (n = 412), this study also 
typiﬁ ed healthy individuals (n = 215), whose geographical 
region and social stratus were equal to those of the patients. 
Furthermore, individuals of mixed heritage predominated, 
followed by white and black individuals, resulting in a highly 
miscegenated sample (mainly descendants from Portuguese, 
Africans, Indians, Italians, Spaniards, and German), which we 
believe partially reﬂ ects the Brazilian population itself.
In theory, in genetic studies, age would not inﬂ uence sus-
ceptibility. However, because of the presence of HLA-DRB1 
SE+ alleles in 12.5% to 35%23,38 of the healthy population, 
and the higher incidence of RA between 30 and 55 years,2 we 
tried to avoid analysis biases regarding the diagnosis in the 
control group by including in our control group individuals 
with more advanced age.
Regarding the HLA-DRB1 and disease association, an 
increased frequency of the HLA-DRB1*04:01, *04:04 and 
*04:05 alleles and a positive association with susceptibility to 
RA have been observed. This result is partially in accordance 
with those by Louzada-Junior et al.23 in the predominantly 
Caucasian Brazilian population, in which, in addition to the 
association with the previously cited alleles, an association with 
the HLA-DRB1*01:01 allele has also been reported. However, 
this differs from the ﬁ ndings of Bertolo et al.,22 who have re-
ported a signiﬁ cant association only with the HLA-DRB1*01 
alleles (OR = 2.8), also assessing Caucasian populations.
Similarly to that observed by Louzada-Junior et al.,22 the 
HLA-DRB1*14:02 allele has shown a tendency towards the 
association with RA, although not signiﬁ cantly (OR = 3.18; 
95% CI 0.88-13.63; P = 0.086). Studies with a higher number 
of individuals might show statistical signiﬁ cance in this as-
sociation. A study with a mixed Peruvian population (n = 65) 
has shown that the HLA-DRB1*14:02 allele and RA are as-
sociated (OR = 2.74).18
The HLA-DRB1*09 alleles, which predominate in black 
and Indian descendants, present in 6.7% of RA patients and in 
1.3% of controls showed a signiﬁ cant association with suscep-
tibility to RA in the heterozygous genotypes of these alleles 
(OR = 5.19; 95% CI 1.50-21.49; P = 0.004). Despite the wide 
conﬁ dence interval observed, this allele was for the ﬁ rst time 
associated with susceptibility to RA in the Brazilian popula-
tion. That same association (HLA-DRB1*09 and RA) was also 
reported in Chilean patients with RA in 1990.39 However, a 
study carried out in Japan with 852 RA patients found only the 
association of the homozygous HLA-DRB1*09:01 genotype 
with the disease.36 
Similarly to the studies by Vignal et al.35 (OR = 5.04) and 
Balsa et al.38 (OR = 1.8) including an ethnically homogeneous 
population, we also found an association between the set of 
HLA-DRB1 SE+ alleles and RA (OR = 3.59). This result dif-
fers from the one reported by Teller et al.40 in a study including 
RA patients and Hispanic-American controls, in which no as-
sociation between these alleles and the disease was observed, 
suggesting that the hypothesis of the SE might not be applied 
in studies with non-mixed populations.
In the present study, an increased frequency of the heterozy-
gous HLA-DRB1 SE genotypes (51%) can be observed when 
compared with RA patients and controls with homozygous 
genotypes (11%). In a study by del Rincon et al.,41 heterozygous 
SE genotypes were observed in 52% of RA patients, and ho-
mozygous SE genotypes in 22%. However, Balsa et al.38 have 
reported 29.8% and 14% of heterozygous and homozygous 
patients, respectively. In this study, after logistic regression 
analysis of homozygous and heterozygous HLA-DRB1 SE+ 
genotypes, patients with SE, regardless of being homozygous 
(OR = 3.86) or heterozygous (OR = 3.54), showed an increased 
risk but of similar OR for the development of RA. This result 
is not in accordance with the study by del Rincon et al.,41 in 
which the assessment of 141 Mexican patients with RA showed 
a higher risk for homozygous SE genotypes (OR = 21.53) as 
compared with heterozygous SE genotypes (OR = 1.84). 
Regarding the protective HLA-DRB1 alleles against RA, 
HLA-DRB1 alleles encoding the DERAA amino acid sequence 
were observed to associate with a lower risk for developing RA 
(OR = 0.42), similarly to that reported by Louzada-Junior et 
al.23 in 2008 (OR = 0.49). Carrier et al.25 have assessed patients 
with recent-onset polyarthritis, and have reported that DERAA 
alleles were neither associated with the production of autoan-
tibodies, nor showed a protective effect on the development 
of RA (OR = 0.30). More recently, Balsa et al.38 have reported 
that these alleles provide protection against RA only in the 
presence of circulating ACPA (OR = 0.58). Another study has 
shown that DERAA alleles, in addition to protecting against 
RA, are associated with less severe illness.24
We observed a higher frequency of RF (62%) and ACPA 
(71%) positivity as compared with a group of Brazilian patients 
with initial RA,42 whose frequencies were approximately 50%. 
This result can be due to the fact that our group of patients has 
a longer duration of disease (approximately nine years). The 
HLA-DRB1 SE alleles were related to the RF and ACPA posi-
tivity, but only the association with the presence of ACPA was 
signiﬁ cant (Table 6). In 2005, Irigoyem et al.29 reported a strong 
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association between ACPA and SE alleles, independently of 
the presence of RF (OR = 5.8; 95% CI 4.1-8.3; P < 0.001; 
and OR = 3.1; 95% CI 1.8-5.3; P < 0.001). Similarly to that 
observed by Balsa et al.,38 this study showed that homozygous 
HLA-DRB1 SE genotypes had higher serum levels of ACPA 
as compared with those of the heterozygous genotypes and the 
patients without SE. In contrast, the serum levels of RF did not 
differ in patients with and without the SE alleles. We observed 
that of 27 patients with the HLA-DRB1*09 allele, 88.8% had 
ACPA and 85% had RF, suggesting that mechanisms other 
than SE would be implicated in the genetic risk for develop-
ing RF and ACPA.
Brieﬂ y, this study, with a population sample of predomi-
nantly mixed heritage and more representative of the Brazilian 
population, evidenced that the HLA-DRB1*04:01, *04:04, and 
*04:05 alleles were associated with an increased susceptibility 
to RA, and also emphasized the association with the DRB1*09 
allele in these patients. Our results support the association 
between DRB1 SE alleles and susceptibility to RA and ACPA 
previously reported in studies with genetically homogeneous 
population samples. In addition, we showed that the presence 
of the SE allele, either in a single or double dose, acted as an 
independent risk factor for the disease, and the presence of the 
DERAA alleles showed a protective effect. Furthermore, the 
HLA-EC alleles were associated with higher positivity and 
higher serum levels of ACPA. Although the Brazilian Society of 
Rheumatology guidelines for the diagnosis of RA established in 
201143 recommend that the HLA-EC measurement should not 
be a daily routine test in the management of patients suspected 
of having RA because of its high cost, our study conﬁ rms its 
importance in establishing the risk for and protective factors 
against the development of RA. 
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